222 related articles for article (PubMed ID: 29308306)
1. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.
Keung EZ; Tsai JW; Ali AM; Cormier JN; Bishop AJ; Guadagnolo BA; Torres KE; Somaiah N; Hunt KK; Wargo JA; Lazar AJ; Wang WL; Roland CL
Oncoimmunology; 2018; 7(2):e1385689. PubMed ID: 29308306
[No Abstract] [Full Text] [Related]
2. The immune landscape of undifferentiated pleomorphic sarcoma.
Lazcano R; Barreto CM; Salazar R; Carapeto F; Traweek RS; Leung CH; Gite S; Mehta J; Ingram DR; Wani KM; Vu KT; Parra ER; Lu W; Zhou J; Witt RG; Cope B; Thirasastr P; Lin HY; Scally CP; Conley AP; Ratan R; Livingston JA; Zarzour AM; Ludwig J; Araujo D; Ravi V; Patel S; Benjamin R; Wargo J; Wistuba II; Somaiah N; Roland CL; Keung EZ; Solis L; Wang WL; Lazar AJ; Nassif EF
Front Oncol; 2022; 12():1008484. PubMed ID: 36313661
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
6. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
7. The immune microenvironment of uterine adenosarcomas.
Ali AMR; Tsai JW; Leung CH; Lin H; Ravi V; Conley AP; Lazar AJ; Wang WL; Nathenson MJ
Clin Sarcoma Res; 2020; 10():5. PubMed ID: 32231779
[TBL] [Abstract][Full Text] [Related]
8. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL; Nassif Haddad EF; Keung EZ; Wang WL; Lazar AJ; Lin H; Chelvanambi M; Parra ER; Wani K; Guadagnolo BA; Bishop AJ; Burton EM; Hunt KK; Torres KE; Feig BW; Scally CP; Lewis VO; Bird JE; Ratan R; Araujo D; Zarzour MA; Patel S; Benjamin R; Conley AP; Livingston JA; Ravi V; Tawbi HA; Lin PP; Moon BS; Satcher RL; Mujtaba B; Witt RG; Traweek RS; Cope B; Lazcano R; Wu CC; Zhou X; Mohammad MM; Chu RA; Zhang J; Damania A; Sahasrabhojane P; Tate T; Callahan K; Nguyen S; Ingram D; Morey R; Crosby S; Mathew G; Duncan S; Lima CF; Blay JY; Fridman WH; Shaw K; Wistuba I; Futreal A; Ajami N; Wargo JA; Somaiah N
Nat Cancer; 2024 Apr; 5(4):625-641. PubMed ID: 38351182
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K
Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389
[TBL] [Abstract][Full Text] [Related]
10. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
11. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
[TBL] [Abstract][Full Text] [Related]
12. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.
Mauzo SH; Tetzlaff MT; Milton DR; Siroy AE; Nagarajan P; Torres-Cabala CA; Ivan D; Curry JL; Hudgens CW; Wargo JA; Sahin AA; Pettaway CA; Prieto VG; Aung PP
Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31146499
[TBL] [Abstract][Full Text] [Related]
15. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
16. Case Report: An exceptional response to neoadjuvant radiotherapy and chemotherapy in undifferentiated pleomorphic sarcoma following checkpoint inhibitor use.
Jeon WJ; Moon JH; Pham B; Joung B; Denham L; Brothers J
Front Oncol; 2023; 13():1198292. PubMed ID: 37427109
[TBL] [Abstract][Full Text] [Related]
17. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures.
Cheung LS; Chen L; Oke TF; Schaffer TB; Boudadi K; Ngo JT; Gross JM; Kemberling H; Diaz LA; Lipson E; Sidhom JW; Taube J; Anders R; Pardoll DM; Le DT; Meyer CF; Llosa N
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103354
[TBL] [Abstract][Full Text] [Related]
18. Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.
Wustrack RL; Shao E; Sheridan J; Zimel M; Cho SJ; Horvai AE; Luong D; Kwek SS; Fong L; Okimoto RA
Cancer Immunol Immunother; 2021 Oct; 70(10):3031-3040. PubMed ID: 33864502
[TBL] [Abstract][Full Text] [Related]
19. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer.
Yu Y; Ma X; Zhang Y; Zhang Y; Ying J; Zhang W; Zhong Q; Zhou A; Zeng Y
J Cancer; 2019; 10(12):2754-2763. PubMed ID: 31258783
[TBL] [Abstract][Full Text] [Related]
20. Natural history of undifferentiated pleomorphic sarcoma: Experience from the US Sarcoma Collaborative.
Makris EA; Tran TB; Delitto DJ; Lee B; Ethun CG; Grignol V; Harrison Howard J; Bedi M; Clark Gamblin T; Tseng J; Roggin KK; Chouliaras K; Votanopoulos K; Cullinan D; Fields RC; Cardona K; Poultsides G; Kirane A
J Surg Oncol; 2024 Apr; ():. PubMed ID: 38562002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
